Alphamab Oncology
Research Alphamab Oncology (9966.HK) on Bullrun: market cap HKD 6.67B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker9966.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 6.67B
- Financial periodFY2025
- RevenueCNY 566.24M
- Revenue growth-11.5%
- Net income-CNY 113.94M
- Free cash flow-CNY 153.48M
- Gross margin88.8%
Valuation Snapshot
latest market cap is HKD 6.67B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 566.24M | -CNY 113.94M | -CNY 153.48M | 88.8% | -0.12 | CNY 258.82M | CNY 122.98M | CNY 1.71B |
| FY2024 | CNY 640.08M | CNY 166.34M | CNY 190.56M | 90.6% | 0.17 | CNY 1.11B | CNY 185.96M | CNY 1.83B |
| FY2023 | CNY 218.77M | -CNY 210.59M | -CNY 239.02M | 74.8% | -0.22 | CNY 1.09B | CNY 257.08M | CNY 1.67B |
| FY2022 | CNY 166.85M | -CNY 325.72M | -CNY 429.96M | 73.5% | -0.35 | CNY 1.07B | CNY 345.39M | CNY 1.56B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 6.67B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Alphamab Oncology
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alphamab Oncology's market cap?
Alphamab Oncology's market capitalization is HKD 6.67B.
What does Alphamab Oncology do?
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand.